Pediatric Pertussis in Ambulatory Settings

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age1-18
SponsorAssociation Clinique Thérapeutique Infantile du val de Marne

About this trial

Since 2002, Whooping cough surveillance in pediatric private practice has been set up in France. The results of the first years, 2002-2006, have confirmed the effectiveness of the Pertussis whole-cell (Pw) vaccine and in particular the duration of protection of 9/10 years. After evaluating cases in children vaccinated with Pw vaccines, the study aims today to analyze cases in children vaccinated with Pertussis acellular (Pa) vaccines used since 2002/2003 and to assess, on an outpatient basis, the impact of new vaccine recommendations in France (in 2013, introduction of a 2 + 1 schedule - 8 weeks, 4 months and a 11-month recall - and a 6-year recall, and in 2014, update in the recommendations of exams to be prescribed based on the child's age and vaccination status).

Eligibility criteria

Qualifiers

All children under 18 years old with a pertussis diagnosis is suspected and a biological exam is requested

Disqualifiers

children without symptoms with a household confirmed case

cases for which the pertussis diagnosis was not suspected by the pediatrician

Trial design

Treatments tested in this trial

  • non interventional study

Treatment groups

No treatment groups listed

Sponsors and collaborators

Association Clinique Thérapeutique Infantile du val de Marne

Lead sponsor

GlaxoSmithKline

Collaborator

Sanofi

Collaborator

Merck Sharp & Dohme LLC

Collaborator